Phase I randomized double-blind placebo-controlled study to assess safety, tolerability, and pharmacokinetics
Ended Awarded Last action
- Contract number
- 75N95024F00002
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $305,772
Award facts
- Contract value 9% obligated
-
- $305,772.00 Current, with exercised options
- $3,358,776.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $305,772 |
About this award
This is a $3,358,776 cost-plus-fixed-fee Delivery Order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO). The award is for a Phase I randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of a medical product. The contract is a task order under NIDA's "Phase I Clinical Trials for Development of Neurotherapeutics" Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle. PPD Development LP, a for-profit subsidiary of Thermo Fisher Scientific, provides clinical trial and research support services to federal agencies. The contract does not have a set-aside designation and has an ultimate completion date of June 30, 2026.
Quick answers
Who was awarded contract 75N95024F00002?
75N95024F00002 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on July 15, 2024.
How much is contract 75N95024F00002 worth?
The government has obligated $305,772 on 75N95024F00002. Its potential value, with all options, is $3,358,776.
Is contract 75N95024F00002 an order under another contract?
Yes. 75N95024F00002 is a delivery order under HHSN271201600005I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract 75N95024F00002 competed?
The extent of competition for 75N95024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award